OncoTricks

Liver cancer in the portal vein, Nov 5, 2026

If you remember one thingScore the liver before you pick the drug: every first-line trial enrolled only Child-Pugh A.
Child-Pugh A, no jaundice, ascites or encephalopathy?
no
Outside the trialsDecide with hepatology.
yes
Endoscopy in the last 6 months, varices treated?
yes
Atezolizumab + bevacizumab
not yet
Durvalumab + tremelimumab, or nivolumab + ipilimumabNo bevacizumab, no endoscopy gate.
Memory tricks

ABCDE = Albumin, Bilirubin, Clotting, Distension (ascites), Encephalopathy.

B for bevacizumab, B for bleeding: scope first.

STRIDE = Single Tremelimumab, Regular Interval Durvalumab.

Sources

Retrieved from PubMed, read on Nov 5, 2026.

  1. Finn RS, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma (IMbrave150). N Engl J Med 2020. doi:10.1056/NEJMoa1915745
  2. Abou-Alfa GK, et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (HIMALAYA). NEJM Evid 2022. doi:10.1056/EVIDoa2100070
  3. Yau T, et al. Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW). Lancet 2025. doi:10.1016/S0140-6736(25)00403-9